Informa Pharma Intelligence releases Citeline's next generations of Sitetrove, Trialtrove and new API solutions
The industry's most comprehensive clinical trial data and analysis, now delivered to better fit customers' individual needs and workflows
Summary: Informa Pharma Intelligence announces three major releases for its clinical R&D Intelligence suite. The same leading global intelligence trusted by thousands worldwide for over 35 years is now backed by even more powerful, cutting edge technology. These new solutions will allow users to go deeper with clinical trial research than ever before, and will offer new options to help users better integrate Citeline's leading content with their own data.
LONDON, June 19, 2017 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the leading provider of drug, device, company, clinical trial, and market intelligence in the competitive pharma and medtech markets announces today the launch of its next generation of Citeline's Sitetrove and Trialtrove solutions, as well as new application programming interfaces (APIs) for Trials and Drugs. The new solutions are designed to deliver unparalleled access to Citeline's robust clinical trial intelligence with greater ease, speed and efficiency than ever before.
"Our next generation of clinical R&D Intelligence solutions are truly market driven," said Linda Blackerby, President of Informa Pharma Intelligence. "We have partnered with hundreds of customers to understand their data needs and workflows, and have developed our new Citeline platform and APIs based directly on their feedback."
The new Trialtrove and Sitetrove provides users with the ability to go even deeper with search criteria to make better and more well-informed critical decisions, gain competitive advantage, save costs on and optimize ROI for their clinical trials. The new APIs will also come with Informa's acclaimed Ask-the-Analyst service, connecting users with therapeutic expert analysts whose average response time to queries is 24 hours or less.
Informa's new Trials and Drugs APIs will enable users to search or stream information directly from Citeline's R&D Intelligence databases into their own systems and embed Informa's quality datasets directly into their own organization's data and workflows, minimizing duplicated effort and time spent acquiring and manipulating data.
"Clinical R&D professionals need to design strategies, develop protocols, plan and execute trials that are on budget and on time," said Nicola Marlin, Vice President of Product. "Our team of scientific analysts live and breathe the data universe to bring our customers a deep understanding of the current clinical trial landscape. The new Citeline platform and API solutions allow users to enjoy the same depth and breadth of specialized, high caliber content, delivered the way they want to better fit their need, internal solutions, and workflows."
"These new releases further reinforce our commitment to our customers to help them gain critical insights into the global clinical trial landscape, realize greater cost-savings and ROI as they develop on their clinical trial programs," stated Michael Hay, Head of Intelligence. "No other intelligence solution comes close."
Attendees at this week's DIA and BIO International conferences will get a sneak preview of these next generation solutions, which will begin launching to customers in July. Additional solutions including the next generation of Citeline's Pharmaprojects and additional APIs for Investigators and Sites are in development for launch later this year.
For more information, visit pharmaintelligence.informa.com.
About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo - to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
Citeline, part of Informa's Pharma Intelligence vertical, is the world's most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched intelligence collection and enrichment of global clinical trials, clinical trial investigator profiles and drug development pipelines.
Citeline is the R&D Intelligence arm of Informa's Pharma Intelligence vertical, one of the world's leading providers of drug, device, company, clinical trial and market intelligence in the pharma and medtech markets. For more information, visit pharmaintelligence.informa.com.
T: (212) 652-5302
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Informa Business Intelligence via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Nasdaq Welcomes Secoo Holding Limited (Nasdaq: SECO) to The Nasdaq Global Market22.9.2017 21:11 | Pressmeddelande
NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Secoo Holding Limited (Nasdaq:SECO), Asia's largest online integrated upscale products and services platform, rang the opening bell at the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Global Market. Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/45f7dc57-524d-4463-a839-d201c341a0f1 http://www.globenewswire.com/NewsRoom/AttachmentNg/149603ca-4949-4531-bf94-aeb6ded2e6df http://www.globenewswire.com/NewsRoom/AttachmentNg/e80a55e0-3858-41cb-80d3-9c9296d6143a Secoo is a consumer-focused online retail platform that offers offline experience centers to provide customer support and membership services. Secoo has built a trusted and comprehensive global supply chain for upscale produ
Alipay teams up with Nordic partners to bring "smart tourism" to Chinese visitors22.9.2017 11:42 | Pressmeddelande
HANGZHOU, China, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Alipay, the world's largest online and mobile payment platform, operated by Ant Financial Services Group ("Ant Financial", "Ant"), today announced that it has signed separate MoUs with Finpro (Finland), Svensk Handel (Sweden) and the Scandinavian Tourist Board, which will enable merchants across Nordic region to accept payment via Alipay and reach Chinese customers before, during and after their visit via Alipay's in-app marketing platform. This will bring Chinese tourists the same convenient payment and travel experience that they enjoy in China. Douglas Feagin, President of International Business, Ant Financial Services Group, said, "Alipay has been leading the trend of smart living in China. People not only use Alipay for payment, but also for settlement of all types of needs in their daily life. As part of our globalization strategy, we are focused on working with local partners to bring this
OpenAire brings in the sun with retractable structures across Europe22.9.2017 08:00 | Pressmeddelande
OAKVILLE, Ontario, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Venues around the world have been thrilled by OpenAire's retractable roof and enclosure designs since 1989. In 28 years, OpenAire's team of experts has completed nearly 1,000 unique retractable roof enclosures and operable skylights for venues of every size and kind internationally, including many groundbreaking designs across Europe. From Russia to warm and sunny Gibraltar, OpenAire has provided many commercial enterprises, resorts and even some private residences with beautiful retractable enclosures that suit their location and climate perfectly. OpenAire works closely with every client from the start, providing them with the flexibility to make their visions a reality. Many clients across Europe have seen increased business and excellent reviews after building an OpenAire solution. Some notable OpenAire designs include: Aqua Sferra's record-breaking 5,667 m2 (60,999 sq. ft.) free-standing aluminum dome housing its indoor
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum